(Reuters) – Moderna Inc <MRNA.O> said on Wednesday it has completed case accrual for the first interim analysis of the late-stage trial of its COVID-19 vaccine candidate.
The company said data on these cases is being prepared for submission to the independent Data Safety Monitoring Board for analysis and recommendation.
Moderna expects the first interim analysis to include more than 53 cases.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)
Manhattan DA says ‘Neighborhood Navigator’ program has helped more than 700 people get essential aid, including housing and mental health
QC New York expands with 15,000-square-foot Building 111 on Governors Island
Op-ed: Fentanyl is killing thousands – it’s time to stop it
NYC subway cleaners who worked during COVID-19 peak are owed back wages, judge rules
amNewYork’s 2024 Year in Review: Ranking the top 24 New York athletes of the year
A look ahead: What does 2025 hold for interest rates, inflation?
Juan Soto sets record straight on Yankees’ treatment of family
Mikal Bridges easing any concerns that he won’t fit with Knicks
Sixers celebrate Christmas with 118-114 win over Celtics in Boston
Advocates hold prayer vigil in Brooklyn for woman burned alive on F train, demand officials stem violence on subways
Israeli Consul General Ofir Akunis talks war in Gaza, antisemitism during visit to Philadelphia
History Column: Preserving historic train stations in Philadelphia
MTA needs to take additional money-saving measures, DiNapoli audit finds in wake of capital plan veto
2025 Mummers Parade: What to expect for the fan-favorite event
